Allergan moves Botox (onabotulinumtoxin A)into Phase III as a potential new treatment option for patients with depression.
Allergan claims to be encouraged by Phase II proof of concept data and the potential impact on adults with major depressive disorder and plans to move forward and develop a phase III program for Botox (onabotulinumtoxin A) as a potential new treatment option for patients.
Comment:The topline data from the Phase II trial compared a 30 unit dose and a 50 unit dose against a placebo for 24 weeks. The primary endpoint for the study was change from baseline at six weeks on the Montgomery-Asberg Depression Rating Scale (MADRS). However neither dose showed statistically significant improvement over placebo but the lower dose did show "numerically superior" data.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.